Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients

Pediatric Blood and Cancer

Volumn 49, Issue 7, 2007, Pages 924-927

  Jacobs, Joannes F M ^a   Hoogerbrugge, Peter M ^a   Van De Rakt, Mandy W M M ^a   Aarntzen, Erik H J G ^a   Figdor, Carl G ^a   Adema, Gosse J ^a   De Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Developmental therapeutics; Immunotherapy; Pediatric oncology; Vaccines

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOKINE; TUMOR ANTIGEN;

ADOLESCENT; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL MIGRATION; CELL STIMULATION; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE;

ADOLESCENT; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; CYTOKINES; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INFANT; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; NEOPLASMS; T-LYMPHOCYTES;

EID: 35648949843     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21246     Document Type: Article

References (28)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
3. Conrad C, Nestle FO. Dendritic cell-based cancer therapy. Curr Opin Mol Ther 2003;5:405-412.
4. Reichardt VL, Brossart P, Kanz L. Dendritic cells in vaccination therapies of human malignant disease. Blood Rev 2004;18:235-243.
5. Davis ID, Jefford M, Parente P, et al. Rational approaches to human cancer immunotherapy. J Leukoc Biol 2003;73:3-29.
6. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998;46:82-87.
7. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-5100.
8. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-17.
9. Ridolfi R, Riccobon A, Galassi R, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004;2:27.
10. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
11. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 2001;93:243-251.
12. Heitger A, Greinix H, Mannhalter C, et al. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation 2000;69:2366-2373.
13. Mackall CL, Fleisher TA, Brown MR, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-149.
14. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol 2004;6:236-246.
15. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001;61:8513-8519.
16. Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91:1656-1662.
17. De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 2004;100:492-497.
18. Maecker B, Mougiakakos D, Zimmermann M, et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006;20:645-649.
19. Redlinger RE Jr, Mailliard RB, Barksdale EM Jr. Neuroblastoma and dendritic cell function. Semin Pediatr Surg 2004;13:61-71.
20. Nabarro S, Himoudi N, Papanastasiou A, et al. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J Exp Med 2005;202:1399-1410.
21. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
22. Figdor CG, de Vries IJ, Lesterhuis WJ, et al. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004;10:475-480.
23. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27:3135-3142.
24. Vakkila J, Vettenranta K, Sariola H, et al. Poor yield of dendritic cell precursors from untreated pediatric cancer. J Hematother Stem Cell Res 2001;10:787-793.
25. Pospisilova D, Borovickova J, Rozkova D, et al. Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Med Oncol 2005;22:79-88.
26. Takayama T, Morelli AE, Onai N, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: Impact on chemotactic responses and in vivo homing ability. J Immunol 2001;166:7136-7143.
27. Parlato S, Santini SM, Lapenta C, et al. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: Importance for the rapid acquisition of potent migratory and functional activities. Blood 2001;98:3022-3029.
28. Kellermann SA, Hudak S, Oldham ER, et al. The CC chemokine receptor-7 ligands 6Ckine and macrophage inflammatory protein-3 beta are potent chemoattractants for in vitro- and in vivo-derived dendritic cells. J Immunol 1999;162:3859-3864.